Toronto, Ontario--(Newsfile Corp. - October 11, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that it will commence trading on the TSX Venture Exchange on October 11^th, 2023. The initial trading price is CDN $2.75.

The Company also announced that Barry Fishman, a seasoned pharma executive has joined the Company's board of directors as an independent director. Mr. Fishman was recently appointed as Chief Corporate Development Officer of Apotex Inc. He has almost 25 years of experience as an entrepreneurial business leader, most recently as CEO of VIVO Cannabis Inc. Prior to joining VIVO, Mr. Fishman served as CEO of international specialty pharmaceutical company Merus Labs, through its 2017 acquisition by Norgine M.V. Mr. Fishman also previously served as CEO of Teva Canada and Vice President of Marketing of Eli Lilly Canada. He has also recently served as an independent director on several high-profile boards, including Aurora Cannabis Inc. and Canopy Growth Corporation. Mr. Fishman graduated from McGill University with a concentration in finance and went on to become a CPA while working for Deloitte in Southern California.

"Listing on the TSX Venture Exchange is a momentous first step in our thousand-mile journey pursuing Pharma Research & Development of novel therapies," said Dr. Raza Bokhari, Executive Chairman & CEO. "We are very excited to welcome Barry Fishman to our board of directors. It is needless to state that his experience and expertise is a remarkable addition to our board of directors, which also includes former CEOs of Siemens Medical, ParenteBeard Baker Tilly, Temple Health System and a former senior executive of Amgen."

The Company has retained Stockhouse Publishing Ltd. ("Stockhouse") and Hybrid Financial Ltd. ("Hybrid") to increase market and brand awareness for Medicus and to broaden Medicus's reach within the investment community. Subject to the TSX Venture Exchange's approval, the Company has also retained Generation IACP Inc. ("Generation IACP") to provide market making services with the objective of maintaining a reasonable market and improving the liquidity of Medicus's common shares.

Stockhouse, Hybrid and General IACP are retained by Medicus pursuant to the following terms:

• Stockhouse has been engaged for a period of six months starting on October 1^st, 2023. Stockhouse will be paid a monthly fee of CDN$ 10,000, plus applicable taxes, during the term of the engagement;
• Hybrid has been engaged for a period of six months starting on October 10^th, 2023. Hybrid will be paid a monthly fee of CDN$ 15,000, plus applicable taxes, during the term of the engagement; and
• Generation IACP has been engaged (subject to the TSX Venture Exchange's approval) for a period of six months starting on October 10^th, 2023. Generation IACP will be paid a monthly fee of CDN$ 7,500, plus applicable taxes, during the term of the engagement.

Medicus has had no prior relationship with Stockhouse, Hybrid or Generation IACP, and to Medicus's knowledge, none of Stockhouse, Hybrid and Generation IACP owns or controls, directly or indirectly, any securities of Medicus.

The Company's board of directors has also approved provisionally the issuance to the Company's directors, officers and advisors of options to buy an aggregate of up to 1,625,000 of the Company's common shares, at a price to be determined in accordance with the policies of the TSX Venture Exchange. The options will be issued in accordance with the Company's stock option plan and subject to vesting terms.

For further information contact:

Medicus Pharma Ltd.
Carolyn Bonner, President
(610) 636-0184
madesso@medicuspharma.com

About Medicus Pharma Ltd:

Medicus Pharma Ltd. (TSXV: MDCX) is a clinical stage, multi-strategy holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA approved clinical trials.

Through our diverse experience and extensive industry network, we are building Medicus into a leading pharmaceutical holding company, committed to delivering better treatment outcomes and alleviating pain and suffering. Utilizing a thesis driven collaborative process, we identify, acquire and advance relatively de-risked clinical stage assets through clinical development and commercialization.

We look into opportunities across all therapeutics areas where an unmet need exists for improved patient safety and efficacy. Medicus is actively exploring to expand its drug development pipeline through qualified and accretive acquisitions and partnerships.

Cautionary Notice on Forward-Looking Statements

Certain information in this news release constitutes "forward-looking information" under applicable securities laws. "Forward-looking information" is defined as disclosure regarding possible events, conditions or financial performance that is based on assumptions about future economic conditions and courses of action and includes future-oriented financial information with respect to prospective financial performance, financial position or cash flows that is presented as a forecast or a projection. Forward-looking statements are often but not always, identified by the use of such terms as "may", "might", "will", "will likely result", "would", "should", "estimate", "plan", "project", "forecast", "intend", "expect", "anticipate", "believe", "seek", "continue", "target" or the negative and/or inverse of such terms or other similar expressions.

These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including: the timing of the listing, including the risks that the conditions to the listing will not be satisfied within the expected timeframe or at all; the ability of the Company to continue as a going concern; the ability of the Company to maintain compliance with certain financial and other covenants; the effects of the epidemics and pandemics; changes in economic conditions; competition; risks and uncertainties applicable to the businesses of the Company and the decentralized finance industry generally, in Canada and abroad; and other risks, uncertainties and factors. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Readers are cautioned that the foregoing list is not exhaustive and readers are encouraged to review the Prospectus accessible on the Company's profile on SEDAR+ at . Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/

To view the source version of this press release, please visit